Hemophilia
Conditions
Keywords
Haemophilia, Arthropathy, Pain, Range of motion, Miofascial techniques
Brief summary
Designing a treatment protocol using myofascial therapy for the treatment of pain and restrictions on mobility in patients with hemophilic arthropathy of the knee and ankle. Pilot with a small number of patients for assessment the effectiveness and safety of the treatment protocol created. Randomized clinical trial to assess the effectiveness of treatment with myofascial therapy in patients with hemophilia. Describe the differences in terms of the dependent variables (range of motion, pain and flexibility) in patients with hemophilia who have carried out the treatment. Report the relationship between the clinical characteristics of patients and the results obtained after the treatment period.
Detailed description
Phase I pilot study with 5 patients with hemophilia for assessment by myofascial therapy protocol designed for this purpose. Phase II. Randomized, prospective longitudinal clinical study in patients with hemophilia, to assess the efficacy of an intervention with myofascial therapy.
Interventions
OTHERMyofascial therapy
Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
Sponsors
Universidad Católica San Antonio de Murcia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of hemophilia A and B. * Patients older than 18 years. * Patients with a diagnosis of hemophilic arthropathy of the knee and ankle. * Patients on prophylactic regimen with FVIII / FIX.
Exclusion criteria
* Patients without walking ability. * Patients with a diagnosis of other congenital coagulopathy (eg von Willebrand disease). * Patients who have developed antibodies to FVIII / FIX (inhibitors). * Patients with neurological or cognitive impairments that impede understanding of questionnaires and physical test. * Patients who have not signed the informed consent document.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bleeding frequency | Screening visit, within the first seven days after treatment and after one month follow-up visit | Change from number of bleeding during treatment and follow-up period at 1 month |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain | Screening visit, within the first seven days after treatment and after one month follow-up visit | Change from joint pain during treatment and follow-up period at 1 month |
| Joint function | Screening visit, within the first seven days after treatment and after one month follow-up visit | Change from joint health during treatment and follow-up period at 1 month. Haemophilia Joint Health. Measurement instrument: Score and Gilbert score |
| Range of motion | Screening visit, within the first seven days after treatment and after one month follow-up visit | Change from range of movement of ankle and knee during treatment and follow-up period at 1 month. Measurement instrument: universal goniometer with the protocol to measurement for patients with hemophilia |
Countries
Spain
Contacts
Primary ContactRUBEN CUESTA-BARRIUSO, PhD
Outcome results
None listed